Autor/a:
|
Aguado, José María; Silva, J. T.; Fernández Ruiz, Mario; Cordero, Elisa; Fortún, J.; Gudiol González, Carlota; Martínez Martínez, L.; Vidal, Elisa; Almenar, Luis; Almirante, Benito; Cantón, Rafael; Carratalà, Jordi; Caston, J. J.; Cercenado, E.; Cervera, Carlos; Cisneros, José Miguel; Crespo Leiro, María G.; Cuervas Mons, V.; Elizalde Fernández, J.; Fariñas, María Carmen; Gavaldà, Joan; Goyanes, M. J.; Gutiérrez Gutiérrez, B.; Hernández, D.; Len, Óscar; López Andújar, Rafael; López Medrano, Francisco; Martín Dávila, Pilar; Montejo, Miguel; Moreno Camacho, Ma. Asunción; Oliver, Antonio; Pascual López, Antonio; Pérez Nadales, E.; Román Broto, A.; San Juan, Rafael; Serón Micas, Daniel; Solé- over, A.; Valerio, Maricela; Muñoz, P.; Torre Cisneros, Julián
|
Notas:
|
Solid organ transplant (SOT) recipients are especially at risk of developing infections by multidrug resistant (MDR) Gram-negative bacilli (GNB), as they are frequently exposed to antibiotics and the healthcare setting, and are regulary subject to invasive procedures. Nevertheless, no recommendations concerning prevention and treatment are available. A panel of experts revised the available evidence; this document summarizes their recommendations: (1) it is important to characterize the isolate's phenotypic and genotypic resistance profile; (2) overall, donor colonization should not constitute a contraindication to transplantation, although active infected kidney and lung grafts should be avoided; (3) recipient colonization is associated with an increased risk of infection, but is not a contraindication to transplantation; (4) different surgical prophylaxis regimens are not recommended for patients colonized with carbapenem-resistant GNB; (5) timely detection of carriers, contact isolation precautions, hand hygiene compliance and antibiotic control policies are important preventive measures; (6) there is not sufficient data to recommend intestinal decolonization; (7) colonized lung transplant recipients could benefit from prophylactic inhaled antibiotics, specially for Pseudomonas aeruginosa; (8) colonized SOT recipients should receive an empirical treatment which includes active antibiotics, and directed therapy should be adjusted according to susceptibility study results and the severity of the infection. |